Menu Search
Equities

Purple Biotech Ltd

1YI1:FRA

Purple Biotech Ltd

Actions
  • Price (EUR)0.725
  • Today's Change0.07 / 10.69%
  • Shares traded-1.00
  • 1 Year change-54.40%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 07:14 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

  • Revenue in USD (TTM)0.00
  • Net income in USD-18.76m
  • Incorporated1968
  • Employees20.00
  • Location
    Purple Biotech Ltd4 Oppenheimer St., Science ParkREHOVOT 7670104IsraelISR
  • Phone+972 39333121
  • Fax+972 35097196
  • Websitehttps://purple-biotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.